



DOCKET NO. 361331-009Re
SERIAL NO. 09/465,444

**APPENDIX A1: PENDING CLAIMS (MARKED FOR CHANGES WITH RESPECT TO THE
ISSUED PATENT)**

What is claimed is:

1. Monoclonal antibody 4G9 produced by hybridoma 4G9, deposited with the American Type Culture Collection (ATCC) and assigned Accession Number CRL 11626, or an antigen binding fragment thereof reactive with in vivo produced advanced glycosylation endproducts (AGEs).
2. The monoclonal antibody or antigen binding fragment thereof of claim 1, which specifically binds to serum-AGE proteins, serum-AGE lipids, serum-AGE peptides, LDL-AGE, Hb-AGE, or collagen-AGE.
3. A humanized or chimetic human-murine antibody of the monoclonal antibody of claim 1.
4. The antigen-binding fragment of the monoclonal antibody of claim 1, selected from the group consisting of a single chain Fv fragment, an F(ab') fragment, an F(ab) fragment, and an F(ab')₂ fragment.
5. The monoclonal antibody or fragment thereof of claim 1 which is a murine IgG isotype antibody.
6. A labeled antibody wherein the antibody is the antibody of claim 1.
7. A hybridoma deposited with the American Type Culture Collection (ATCC) and assigned Accession Number CRL 11626.

**APPENDIX A1: PENDING CLAIMS (MARKED FOR CHANGES WITH RESPECT TO THE
ISSUED PATENT) – (continued)**

8. A pharmaceutical composition containing an anti-AGE antibody in combination with a pharmaceutically acceptable carrier; wherein said anti-AGE antibody is the monoclonal antibody in accordance with any of claims 1-3 or 4.

9. A monoclonal antibody, or an antigen binding fragment thereof reactive with in vivo produced advanced glycosylation endproducts (AGEs), wherein the antibody or fragment is selected such that antigen binding measured by binding competition by 6-aminocaproic acid browned with glucose matches that of

a reference binding moiety which is monoclonal antibody 4G9 produced by hybridoma 4G9, deposited with the American Type Culture Collection (ATCC) and assigned Accession Number CRL 11626 or a fragment thereof corresponding to the antigen binding fragment.

11. The monoclonal antibody or antigen binding fragment thereof of claim 9, which specifically binds to serum-AGE proteins, serum-AGE lipids, serum-AGE peptides, LDL-AGE, Hb-AGE, or collagen-AGE.

12. A humanized or chimeric human-murine antibody of the monoclonal antibody of claim 9.

13. The antigen-binding fragment of the monoclonal antibody of claim 9, selected from the group consisting of a single chain Fv fragment, an F(ab') fragment, an F(ab) fragment, and an F(ab')₂ fragment.

**APPENDIX A1: PENDING CLAIMS (MARKED FOR CHANGES WITH RESPECT TO THE
ISSUED PATENT) – (continued)**

14. The monoclonal antibody or fragment thereof of claim 9, which is a murine IgG isotype antibody.

15. A labeled antibody wherein the antibody is the antibody of claim 9.

16. A pharmaceutical composition containing an anti-AGE antibody in combination with a pharmaceutically acceptable carrier; wherein said anti-AGE antibody is the monoclonal antibody in accordance with any of claims 9, 11-12 or 13.



DOCKET NO. 361331-009Re
SERIAL NO. 09/465,444

APPENDIX B1: REPLACEMENT PARAGRAPHS

Please replace the paragraph at 1:6-10 with the following:

C1

The present Application is a Continuation-In-Part of application Ser. No. 08/367,507, filed Dec. 30, 1994, now US Patent No. 5,744,318, titled A MONOCLONAL ANTIBODY SPECIFIC FOR ADVANCED GLYCOSYLATION ENDPRODUCTS IN BIOLOGICAL SAMPLES [, now pending].